aclarubicin and Hodgkin-Disease

aclarubicin has been researched along with Hodgkin-Disease* in 3 studies

Reviews

1 review(s) available for aclarubicin and Hodgkin-Disease

Article	Year
The anthracycline antineoplastic drugs. The New England journal of medicine, 1981, Jul-16, Volume: 305, Issue:3 Topics: Aclarubicin; Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Carubicin; Daunorubicin; Doxorubicin; Female; Glycosides; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma; Naphthacenes; Ovarian Neoplasms; Sarcoma	1981

Trials

1 trial(s) available for aclarubicin and Hodgkin-Disease

Article	Year
[Co-operative on salvage chemotherapy with VP-16 for malignant lymphoma. Hanshin Study Group on Treatment for Hematological Disorders]. Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:4 Forty one patients with refractory malignant lymphoma were treated with a combination of VP-16, ACM, BH-AC, MTX and PDN as a salvage chemotherapy. These patients were either resistant to frontline therapy or refractory in their relapses. Three patients (7%) achieved a complete remission and 14 patients (34%) attained a partial remission. An overall response rate was 41%. Major toxicities were myelosuppression, nausea, and vomiting. However, they were well tolerated. This regimen has been effective in the treatment for the patients with refractory malignant lymphoma. Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Immunoblastic Lymphadenopathy; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisolone	1992

Article

Year

[Co-operative on salvage chemotherapy with VP-16 for malignant lymphoma. Hanshin Study Group on Treatment for Hematological Disorders].

Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:4

Forty one patients with refractory malignant lymphoma were treated with a combination of VP-16, ACM, BH-AC, MTX and PDN as a salvage chemotherapy. These patients were either resistant to frontline therapy or refractory in their relapses. Three patients (7%) achieved a complete remission and 14 patients (34%) attained a partial remission. An overall response rate was 41%. Major toxicities were myelosuppression, nausea, and vomiting. However, they were well tolerated. This regimen has been effective in the treatment for the patients with refractory malignant lymphoma.

Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Immunoblastic Lymphadenopathy; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisolone

1992

Other Studies

1 other study(ies) available for aclarubicin and Hodgkin-Disease

Article	Year
ABEP as primary chemotherapy for Hodgkin's disease. European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:10 20 untreated Hodgkin's disease patients and 1 patient relapsing after radiotherapy (17 stage IIB-IV and 4 stage I-IIA) were given doxorubicin, bleomycin, etoposide and prednisone on a 21-day cycle. The response rate was 95% and 16 patients (76%) achieved complete remission. 4 patients have relapsed 2, 5, 22 and 50 months after treatment. Survival was 100% at a median follow-up of 35 months. However, due to dyspnoea on exertion in 2 patients, bleomycin will be abandoned, and the occurrence of two second malignancies questions the role of etoposide as a leukaemogenic agent. Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Male; Mechlorethamine; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisolone; Prednisone; Procarbazine; Vincristine	1992

Article

Year

ABEP as primary chemotherapy for Hodgkin's disease.

European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:10

20 untreated Hodgkin's disease patients and 1 patient relapsing after radiotherapy (17 stage IIB-IV and 4 stage I-IIA) were given doxorubicin, bleomycin, etoposide and prednisone on a 21-day cycle. The response rate was 95% and 16 patients (76%) achieved complete remission. 4 patients have relapsed 2, 5, 22 and 50 months after treatment. Survival was 100% at a median follow-up of 35 months. However, due to dyspnoea on exertion in 2 patients, bleomycin will be abandoned, and the occurrence of two second malignancies questions the role of etoposide as a leukaemogenic agent.

Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Male; Mechlorethamine; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisolone; Prednisone; Procarbazine; Vincristine

1992